期刊论文详细信息
Diagnostic Pathology
Incident urothelial cancer in the Malmö Diet and Cancer Study: cohort characteristics and further validation of ezrin as a prognostic biomarker
Karin Jirström1  Alexander Gaber1  Björn Nodin1  Karolina Boman1  Gustav Andersson1  Christoffer Wennersten1 
[1] Department of Clinical Sciences, Lund, Division of Oncology and Pathology, Lund University, Skåne University Hospital, Lund, 221 85, Sweden
关键词: Prognosis;    Urothelial cancer;    Ezrin;    Malmö Diet and Cancer;   
Others  :  1149526
DOI  :  10.1186/s13000-014-0189-5
 received in 2014-08-22, accepted in 2014-09-20,  发布年份 2014
PDF
【 摘 要 】

Background

Reduced membranous expression of the cytoskeleton-associated protein ezrin has previously been demonstrated to correlate with poor prognosis in urothelial bladder cancer in several independent studies. The present study provides a first description of clinicopathological characteristics of incident urothelial cancers, not only located to the bladder, in the prospective, population-based cohort study Malmö Diet and Cancer. In addition, the prognostic value of ezrin expression is validated in primary tumours, and the longitudinal expression of ezrin examined in a subset of primary and recurrent tumours (n?=?28).

Methods

Among a total number of 355 incident tumours registered up until Dec 31 2010, 335 were located to the bladder. Immunohistochemical expression of cytoplasmic and membranous ezrin was evaluated in tissue microarrays with primary tumours from 272 cases and recurrent tumours from 28 cases. A combined score of the minimum, mean and maximum fraction and percentage of staining was calculated. Classification regression tree analysis was applied for selection of prognostic cutoff. Kaplan-Meier analysis, log rank test, univariable and multivariable Cox regression proportional hazards¿ modeling were used to evaluate the impact of ezrin expression on 5-year overall survival (OS).

Results

Ezrin expression could be evaluated in 263/272 primary and all 28 recurrent tumours. Membranous but not cytoplasmic ezrin was significantly reduced in recurrent compared to primary tumours (p < 0.001). Low cytoplasmic and membranous ezrin expression were associated with more advanced T-stage (p = 0.004, p < 0.001) and high-grade tumours (p = 0.025, p < 0.001), but not with age, sex, tumour location or smoking status. Both low cytoplasmic and membranous ezrin staining were associated with a significantly reduced 5-year OS (HR = 1.65; 95% CI 1.06-2.57 and HR = 2.51, 95% CI 1.52-4.17), but only low membranous ezrin remained prognostic after adjustment for age, sex, stage, grade and smoking status (HR = 1.69, 95% CI 1.00-2.85).

Conclusions

This study provides a first description of the clinicopathological characteristics of 355 incident urothelial cancers in the Malmö Diet and Cancer Study up until 2010. In addition, the value of ezrin expression as a prognostic biomarker is further consolidated in this type of cancer.

Virtual Slides

The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/13000_2014_189 webcite

【 授权许可】

   
2014 Wennersten et al.; licensee BioMed Central Ltd.

【 预 览 】
附件列表
Files Size Format View
20150405081157358.pdf 1290KB PDF download
Figure 4. 41KB Image download
Figure 3. 20KB Image download
Figure 2. 156KB Image download
Figure 1. 32KB Image download
【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】
  • [1]Green DA, Rink M, Xylinas E, Matin SF, Stenzl A, Roupret M, Karakiewicz PI, Scherr DS, Shariat SF: Urothelial carcinoma of the bladder and the upper tract: disparate twins. J Urol 2013, 189(4):1214-1221.
  • [2]Siegel R, Naishadham D, Jemal A: Cancer statistics, 2013. CA Cancer J Clin 2013, 63(1):11-30.
  • [3]Messer JC, Shariat SF, Dinney CP, Novara G, Fradet Y, Kassouf W, Karakiewicz PI, Fritsche HM, Izawa JI, Lotan Y, Skinner EC, Tilki D, Ficarra V, Volkmer BG, Isbarn H, Wei C, Lerner SP, Curiel TJ, Kamat AM, Svatek RS: Female gender is associated with a worse survival after radical cystectomy for urothelial carcinoma of the bladder: a competing risk analysis. Urology 2014, 83(4):863-867.
  • [4]Boffetta P: Tobacco smoking and risk of bladder cancer. Scand J Urol Nephrol Suppl 2008, 218:45-54.
  • [5]Olfert SM, Felknor SA, Delclos GL: An updated review of the literature: risk factors for bladder cancer with focus on occupational exposures. South Med J 2006, 99(11):1256-1263.
  • [6]Aben KK, Witjes JA, Schoenberg MP, Hulsbergen-van de Kaa C, Verbeek AL, Kiemeney LA: Familial aggregation of urothelial cell carcinoma. Int J Cancer 2002, 98(2):274-278.
  • [7]Steinmaus CM, Nunez S, Smith AH: Diet and bladder cancer: a meta-analysis of six dietary variables. Am J Epidemiol 2000, 151(7):693-702.
  • [8]Sylvester RJ: Natural history, recurrence, and progression in superficial bladder cancer. Sci World J 2006, 6:2617-2625.
  • [9]Raghavan D, Shipley WU, Garnick MB, Russell PJ, Richie JP: Biology and management of bladder cancer. N Engl J Med 1990, 322(16):1129-1138.
  • [10]Masood S, Sriprasad S, Palmer JH, Mufti GR: T1G3 bladder cancer¿indications for early cystectomy. Int Urol Nephrol 2004, 36(1):41-44.
  • [11]Sternberg CN: The treatment of advanced bladder cancer. Ann Oncol 1995, 6(2):113-126.
  • [12]Palou J, Algaba F, Vera I, Rodriguez O, Villavicencio H, Sanchez-Carbayo M: Protein expression patterns of ezrin are predictors of progression in T1G3 bladder tumours treated with nonmaintenance bacillus Calmette-Guerin. Eur Urol 2009, 56(5):829-836.
  • [13]Athanasopoulou A, Aroukatos P, Nakas D, Repanti M, Papadaki H, Bravou V: Decreased ezrin and paxillin expression in human urothelial bladder tumors correlate with tumor progression. Urol Oncol 2013, 31(6):836-842.
  • [14]Andersson G, Wennersten C, Gaber A, Boman K, Nodin B, Uhlen M, Segersten U, Malmstrom PU, Jirstrom K: Reduced expression of ezrin in urothelial bladder cancer signifies more advanced tumours and an impaired survival: validatory study of two independent patient cohorts. BMC Urol 2014, 14:36. BioMed Central Full Text
  • [15]Berglund G, Elmstahl S, Janzon L, Larsson SA: The Malmo Diet and Cancer Study: design and feasibility. J Intern Med 1993, 233(1):45-51.
  • [16]Boman K, Segersten U, Ahlgren G, Eberhard J, Uhlen M, Jirstrom K, Malmstrom PU: Decreased expression of RNA-binding motif protein 3 correlates with tumour progression and poor prognosis in urothelial bladder cancer. BMC Urol 2013, 13(1):17. BioMed Central Full Text
  • [17]Ogino S, Stampfer M: Lifestyle factors and microsatellite instability in colorectal cancer: the evolving field of molecular pathological epidemiology. J Natl Cancer Inst 2010, 102(6):365-367.
  • [18]Ogino S, Chan AT, Fuchs CS, Giovannucci E: Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field. Gut 2011, 60(3):397-411.
  • [19]Lochhead P, Chan AT, Giovannucci E, Fuchs CS, Wu K, Nishihara R, O'Brien M, Ogino S: Progress and opportunities in molecular pathological epidemiology of colorectal premalignant lesions. Am J Gastroenterol 2014, 109(8):1205-1214.
  • [20]Slaughter DP, Southwick HW, Smejkal W: Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer 1953, 6(5):963-968.
  • [21]Li M, Cannizzaro LA: Identical clonal origin of synchronous and metachronous low-grade, noninvasive papillary transitional cell carcinomas of the urinary tract. Hum Pathol 1999, 30(10):1197-1200.
  • [22]Lochhead P, Chan AT, Nishihara R, Fuchs CS, Beck AH, Giovannucci E, Ogino S: Etiologic field effect: reappraisal of the field effect concept in cancer predisposition and progression. Mod Pathol 2014, ?:?. doi:10.1038/modpathol.2014.81. [Epub ahead of print]
  • [23]Furrer D, Jacob S, Caron C, Sanschagrin F, Provencher L, Diorio C: Validation of a new classifier for the automated analysis of the human epidermal growth factor receptor 2 (HER2) gene amplification in breast cancer specimens. Diagn Pathol 2013, 8:17. BioMed Central Full Text
  • [24]Rizzardi AE, Johnson AT, Vogel RI, Pambuccian SE, Henriksen J, Skubitz AP, Metzger GJ, Schmechel SC: Quantitative comparison of immunohistochemical staining measured by digital image analysis versus pathologist visual scoring. Diagn Pathol 2012, 7:42. BioMed Central Full Text
  • [25]Dahlman A, Rexhepaj E, Brennan DJ, Gallagher WM, Gaber A, Lindgren A, Jirstrom K, Bjartell A: Evaluation of the prognostic significance of MSMB and CRISP3 in prostate cancer using automated image analysis. Mod Pathol 2011, 24(5):708-719.
  • [26]Stewart GD, Bariol SV, Grigor KM, Tolley DA, McNeill SA: A comparison of the pathology of transitional cell carcinoma of the bladder and upper urinary tract. BJU Int 2005, 95(6):791-793.
  • [27]Hall MC, Womack S, Sagalowsky AI, Carmody T, Erickstad MD, Roehrborn CG: Prognostic factors, recurrence, and survival in transitional cell carcinoma of the upper urinary tract: a 30-year experience in 252 patients. Urology 1998, 52(4):594-601.
  • [28]Catto JW, Yates DR, Rehman I, Azzouzi AR, Patterson J, Sibony M, Cussenot O, Hamdy FC: Behavior of urothelial carcinoma with respect to anatomical location. J Urol 2007, 177(5):1715-1720.
  • [29]Dayyani F, Pettaway CA, Kamat AM, Munsell MF, Sircar K, Pagliaro LC: Retrospective analysis of survival outcomes and the role of cisplatin-based chemotherapy in patients with urethral carcinomas referred to medical oncologists. Urol Oncol 2013, 31(7):1171-1177.
  • [30]Larsson AH, Nodin B, Syk I, Palmquist I, Uhlen M, Eberhard J, Jirstrom K: Podocalyxin-like protein expression in primary colorectal cancer and synchronous lymph node metastases. Diagn Pathol 2013, 8:109. BioMed Central Full Text
  • [31]Larsson A, Fridberg M, Gaber A, Nodin B, Leveen P, Jonsson G, Uhlen M, Birgisson H, Jirstrom K: Validation of podocalyxin-like protein as a biomarker of poor prognosis in colorectal cancer. BMC Cancer 2012, 12:282. BioMed Central Full Text
  文献评价指标  
  下载次数:126次 浏览次数:21次